ESSA PHARMA INC Other Situations 8-K Filing 2024 - Press Release ESSA Pharma Inc. announced updated dose escalation data from its Phase 1/2 study at the 2024 ASCO Genitourinary Cancers Symposium.Get access to all SEC 8-K filings of the ESSA PHARMA INC